Production (Stage)
AnaptysBio, Inc.
ANAB
$20.44
-$0.30-1.45%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 27.77M | 43.11M | 30.02M | 10.97M | 7.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 27.77M | 43.11M | 30.02M | 10.97M | 7.18M |
| Cost of Revenue | 41.18M | 42.59M | 42.21M | 42.00M | 37.04M |
| Gross Profit | -13.41M | 524.00K | -12.20M | -31.03M | -29.86M |
| SG&A Expenses | 14.13M | 10.19M | 10.56M | 9.30M | 12.34M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 55.31M | 52.78M | 52.77M | 51.29M | 49.38M |
| Operating Income | -27.54M | -9.67M | -22.76M | -40.32M | -42.20M |
| Income Before Tax | -39.29M | -21.79M | -32.85M | -46.65M | -43.94M |
| Income Tax Expenses | 44.00K | -6.00K | -- | 9.00K | -- |
| Earnings from Continuing Operations | -39.33M | -21.78M | -32.85M | -46.66M | -43.94M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.33M | -21.78M | -32.85M | -46.66M | -43.94M |
| EBIT | -27.54M | -9.67M | -22.76M | -40.32M | -42.20M |
| EBITDA | -27.39M | -9.53M | -22.61M | -40.17M | -42.04M |
| EPS Basic | -1.28 | -0.72 | -1.14 | -1.71 | -1.64 |
| Normalized Basic EPS | -0.80 | -0.45 | -0.71 | -1.07 | -1.02 |
| EPS Diluted | -1.28 | -0.72 | -1.14 | -1.71 | -1.64 |
| Normalized Diluted EPS | -0.80 | -0.45 | -0.71 | -1.07 | -1.02 |
| Average Basic Shares Outstanding | 30.64M | 30.45M | 28.89M | 27.36M | 26.80M |
| Average Diluted Shares Outstanding | 30.64M | 30.45M | 28.89M | 27.36M | 26.80M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |